MindBio Therapeutics - Chief Executive, Justin Hanka.
Chief Executive, Justin Hanka.
Source: MindBio Therapeutics.
  • MindBio Therapeutics (MBIO) is now trading on the Canadian Securities Exchange
  • MindBio is among a select group of public psychedelics companies globally conducting Phase 2 human clinical trials
  • It is also the first company in history to have clinical trials approved for LSD take-home use
  • MindBio is a biotech and biopharma company focused on creating treatments for mental health conditions
  • MindBio Therapeutics (MBIO) has received numerous bids, with official share price information to be released later today

MindBio Therapeutics (MBIO) is now trading on the Canadian Securities Exchange.

MindBio is among a select group of public psychedelics companies globally conducting Phase 2 human clinical trials. It is also the only company in the world to have clinical trials approved for LSD take-home use, having successfully completed a Phase 1 LSD microdosing clinical trial in 2022.

Two separate Phase 2 take-home LSD microdosing trials are fully funded and slated to begin shortly.

The company’s shareholders include Negev Capital, a world leading institutional fund focusing on psychedelic medicines, as well as Shape Capital, Hardenbrook Group and Advisir Ventures.

“We are changing the course of mental health treatments and believe that microdosing of psychedelic medicines combined with our proprietary treatment protocols will be a game-changer for the treatment of depression and related mental health conditions at scale in the primary healthcare system,” stated Justin Hanka, MindBio’s Co-Founder and Chief Executive.

“We expect to make a number of strategic announcements over the coming months, including much anticipated positive read outs from our Phase 1 LSD microdosing trial and progress of our two upcoming Phase 2 trials,” he added.

MindBio is a biotech and biopharma company focused on creating treatments for mental health conditions. The company’s scientific team is currently developing an LSD microdosing treatment protocol for at-home use within the primary healthcare system.

MindBio Therapeutics (MBIO) has received numerous bids, with official share price information to be released later today.

The materials provided in this article are for information only and should not be treated as investment advice. For full disclaimer information, please click here.


More From The Market Online
The Market Online Video

With purification plant producing, helium firm focuses on exploration

Royal Helium (TSXV:RHC) is an exploration production and infrastructure company with a focus on the development and production of helium.

How this junior is unlocking unprecedented potential in Alaska 

Freegold Ventures (TSX:FVL) is well-positioned to be a leader in the state of Alaska's gold mining sector and investors are paying attention.

Arbor Metals unearths encouraging results in lithium exploration

Arbor Metals (TSXV:ABR) completes a Phase 2 exploration program at its Jarnet lithium project in a highly prospective region of Québec.

Hillcrest and Ocean Batteries deploy new energy storage systems

Hillcrest Energy Technologies (CSE:HEAT) completes its joint development agreement with Ocean Batteries to deliver its unique equipment.